Show simple item record

dc.contributor.authorCetin, Sibel Erdamar
dc.contributor.authorBatur, Sebnem
dc.contributor.authorKepil, Nuray
dc.contributor.authorWetherilt, Ceyda Sonmez
dc.date.accessioned2021-03-02T23:09:14Z
dc.date.available2021-03-02T23:09:14Z
dc.date.issued2017
dc.identifier.citationKepil N., Batur S., Wetherilt C. S. , Cetin S. E. , "Human epidermal growth factor receptor 2 (HER-2) status evaluation in advanced gastric cancer using immunohistochemistry versus silver in situ hybridization", BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, cilt.17, sa.2, ss.109-113, 2017
dc.identifier.issn1512-8601
dc.identifier.otherav_10c16ec8-ec71-4d1c-b7c8-f3ec548297b1
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/16770
dc.identifier.urihttps://doi.org/10.17305/bjbms.2016.1497
dc.description.abstractAccurate identification of human epidermal growth factor receptor 2 (HER-2) status in advanced gastric cancer patients is of utmost importance in terms of treatment planning. This study aimed to examine the HER-2 status in advanced gastric cancer patients using both immunohistochemistry (IHC) and silver in situ hybridization (SISH) techniques and to investigate concordance and diagnostic accuracy. In addition, associations between clinical parameters and HER-2 status were examined. A total of 313 patients diagnosed with locally advanced (Stage III: T3-4, N+) recurrent or metastatic adenocarcinoma of the stomach or esophagogastric junction, between 2009 and 2015, were included. HER-2 status was examined using both IHC and SISH techniques and the findings were compared. Overall SISH-confirmed HER-2 positivity rate was 22%. Multivariate analysis identified only well-differentiated tumor as a significant predictor of HER-2 positivity (OR: 2.9, 95% CI: 1.4-5.9, p = 0.003). When IHC 2+ and 3+ were considered positive for HER-2 status, sensitivity, specificity, and concordance rate (kappa) was 95.7%, 93.8%, and 0.84, respectively. Corresponding figures when only IHC 3+ cases were considered positive were lower: 50%, 100%, and 0.61, respectively. The present method used for the identification of HER-2 positive gastric cancer patients provides satisfactory results. However, better categorization of IHC 2+ cases has the potential to improve the diagnostic accuracy, which is particularly important when more sophisticated methods are not readily available.
dc.language.isoeng
dc.subjectTıbbi Ekoloji ve Hidroklimatoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, ARAŞTIRMA VE DENEYSEL
dc.titleHuman epidermal growth factor receptor 2 (HER-2) status evaluation in advanced gastric cancer using immunohistochemistry versus silver in situ hybridization
dc.typeMakale
dc.relation.journalBOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume17
dc.identifier.issue2
dc.identifier.startpage109
dc.identifier.endpage113
dc.contributor.firstauthorID238360


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record